Drug Profile
Research programme: allergic asthma therapy - CJ Corporation
Alternative Names: E-CpG ODNLatest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator CJ Corporation
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 29 Aug 2007 Discontinued - Preclinical for Allergic asthma in South Korea (unspecified route)
- 20 Apr 2005 Preclinical trials in Allergic asthma in South Korea (unspecified route)